RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using anastrozole may fight breast cancer by reducing the production of estrogen. Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Combining anastrozole with gefitinib may kill more tumor cells.

PURPOSE: Randomized phase II trial to compare the effectiveness of anastrozole with or without gefitinib in treating postmenopausal women who have metastatic or locally recurrent breast cancer.

Condition	Treatment or Intervention	Phase
recurrent breast cancer stage IIIA breast cancer stage IIIB breast cancer stage IIIC breast cancer stage IV breast cancer	Drug: anastrozole  Drug: gefitinib  Procedure: aromatase inhibition  Procedure: endocrine therapy  Procedure: enzyme inhibitor therapy  Procedure: hormone therapy  Procedure: protein tyrosine kinase inhibitor therapy	Phase II

Further Study Details: 

OBJECTIVES:

• Compare the antitumor activity of anastrozole with vs without gefitinib, in terms of clinical benefit rate, in postmenopausal women with metastatic or locally recurrent advanced breast cancer.
• Compare the objective tumor response and duration of tumor response in patients treated with these regimens.
• Compare the progression-free survival of patients treated with these regimens.
• Compare the safety of these regimens in these patients.

OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study. Patients are stratified according to participating center, dominant site of metastatic disease (bone alone vs other), prior chemotherapy (no vs yes), and stage (metastatic vs locally recurrent). Patients are randomized to 1 of 2 treatment arms.

• Arm I: Patients receive oral anastrozole and oral gefitinib once daily.
• Arm II: Patients receive oral anastrozole and an oral placebo once daily. In both arms, treatment continues in the absence of disease progression or unacceptable toxicity.

Patients are followed every 8 weeks until disease progression.

PROJECTED ACCRUAL: A total of 108 patients (54 per treatment arm) will be accrued for this study.

Genders Eligible for Study:  Both

Criteria

DISEASE CHARACTERISTICS:

• Histologically confirmed breast cancer
• Radiologically or clinically evident metastatic or locally recurrent disease
• Unidimensionally measurable disease
• Failed prior tamoxifen therapy
• No rapidly progressive visceral metastases
• No uncontrolled CNS metastases
• Hormone receptor status:
• Estrogen receptor and/or progesterone receptor positive

PATIENT CHARACTERISTICS: Age

• Postmenopausal

Sex

• Female

Menopausal status

• Postmenopausal, defined by any of the following:
• Natural menopause with last menses more than 1 year ago
• Radiotherapy-induced oophorectomy with last menses more than 1 year ago
• Chemotherapy-induced menopause with last menses more than 1 year ago AND serum follicle-stimulating hormone and luteinizing hormone and plasma estradiol levels clearly in the postmenopausal range
• Surgical castration

Performance status

• ECOG 0-2

Life expectancy

• Not specified

Hematopoietic

• Not specified

Hepatic

• Bilirubin no greater than 1.5 times upper limit of normal (ULN)
• Transaminases no greater than 2.5 times ULN
• No unstable or uncompensated hepatic disease

Renal

• No unstable or uncompensated renal disease

Cardiovascular

• No unstable or uncompensated cardiac disease

Pulmonary

• No unstable or uncompensated pulmonary disease
• No clinically active interstitial lung disease
• Asymptomatic chronic stable radiographic changes are allowed

Other

• No severe or uncontrolled systemic disease
• No other malignancy within the past 5 years except adequately treated carcinoma in situ of the cervix, nonmelanoma skin cancer, or contralateral breast cancer
• No psychological, familial, sociological or geographical condition that would preclude study compliance and follow-up
• No grade 2 or greater unresolved chronic toxicity from prior anticancer therapy
• No unresolved ocular inflammation or infection
• No known hypersensitivity to anastrozole or gefitinib or any of their excipients

PRIOR CONCURRENT THERAPY: Biologic therapy

• No prior trastuzumab (Herceptin)
• No concurrent biologic therapy

Chemotherapy

• No more than 1 line of prior chemotherapy in the adjuvant or metastatic setting
• No concurrent chemotherapy

Endocrine therapy

• At least 2 years since prior aromatase inhibitors (e.g., anastrozole, letrozole, or exemestane) in the adjuvant setting
• Prior tamoxifen or fulvestrant in the adjuvant and/or metastatic setting allowed
• No prior aromatase inhibitors for metastatic disease
• No other concurrent hormonal therapy

Radiotherapy

• No concurrent radiotherapy to any metastatic site

Surgery

• No surgery during and within 4 days after the last dose of gefitinib

Other

• At least 30 days since prior investigational drugs
• No prior anti-epidermal growth factor therapy
• No prior anti-vascular endothelial growth factor therapy (i.e., tyrosine kinase inhibitor receptor)
• No concurrent administration of any of the following drugs:
• Phenytoin
• Carbamazepine
• Rifampin
• Phenobarbital
• Hypericum perforatum (St John's Wort)
• No other concurrent investigational drugs or treatment
• No other concurrent cancer treatment
• No concurrent systemic retinoids
• Concurrent bisphosphonate therapy for the treatment and prevention of bony metastases is allowed provided therapy was initiated prior to study entry
• Bisphosphonates may be initiated during study only for the treatment of hypercalcemia

Belgium
      Institut Jules Bordet, Brussels,  1000,  Belgium; Recruiting
      Ziekenhuis Network Antwerpen Middelheim, Antwerpen,  B-2020,  Belgium; Recruiting
France
      Institut Bergonie, Bordeaux,  33076,  France; Recruiting
Netherlands
      Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam,  1066 CX,  Netherlands; Recruiting
Slovenia
      Institute of Oncology - Ljubljana, LJUBLJANA,  Sl-1000,  Slovenia; Recruiting
United Kingdom, Scotland
      Western General Hospital, Edinburgh,  Scotland,  EH4 2XU,  United Kingdom; Recruiting

Study chairs or principal investigators

Martine J. Piccart-Gebhart, MD, PhD,  Institut Jules Bordet   
Martine J. Piccart-Gebhart, MD, PhD,  Institut Jules Bordet   

Study ID Numbers:  CDR0000315629; EORTC-10021; IDBBC-10021; NCT00066378
Record last reviewed:  March 2005
Last Updated:  March 15, 2005
Record first received:  August 6, 2003
ClinicalTrials.gov Identifier:  NCT00066378
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08